Silence Therapeutics Company Leadership
| SLN Stock | USD 4.50 0.22 4.66% |
Silence Therapeutics employs about 109 people. The company is managed by 15 executives with a total tenure of roughly 255 years, averaging almost 17.0 years of service per executive, having 7.27 employees per reported executive. Analysis of Silence Therapeutics' management performance can provide insight into the firm performance.
Silence |
Silence Therapeutics Management Team Effectiveness
The company has Return on Asset of (0.2727) % which means that on every $100 spent on assets, it lost $0.2727. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.028) %, meaning that it generated no profit with money invested by stockholders. Silence Therapeutics' management efficiency ratios could be used to measure how well Silence Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Silence Therapeutics Workforce Comparison
Silence Therapeutics PLC is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,399. Silence Therapeutics holds roughly 109 in number of employees claiming about 5% of equities under Health Care industry.
Silence Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Silence Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Silence Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Silence Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Griffiths Richard Ian over a week ago Acquisition by Griffiths Richard Ian of 60000 shares of Silence Therapeutics at 4.85 subject to Rule 16b-3 | ||
Romano Steven J. over a month ago Insider Trading |
Silence Therapeutics Notable Stakeholders
A Silence Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Silence Therapeutics often face trade-offs trying to please all of them. Silence Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Silence Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Craig MBA | President Officer | Profile | |
| John Strafford | Alliance Devel | Profile | |
| Rhonda Hellums | Chief Officer | Profile | |
| Eric Floyd | VP Assurance | Profile | |
| Gem Hopkins | Head Communications | Profile | |
| Gianine Esposito | Chief Officer | Profile | |
| Giles MD | Head VP | Profile | |
| Jrgen Wittendorff | VP Manufacturing | Profile | |
| Steven MD | Executive Officer | Profile | |
| J Gabriel | Chief Officer | Profile | |
| MBA MBA | CEO Pres | Profile | |
| Marie Lindholm | Chief Officer | Profile | |
| Dr JD | Senior Officer | Profile | |
| Curtis MD | Chief Officer | Profile | |
| MBA MS | Senior Assurance | Profile |
About Silence Therapeutics Management Performance
The success or failure of an entity such as Silence Therapeutics PLC often depends on how effective the management is. Silence Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Silence management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Silence management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid therapeutics in hematology, cardiovascular, and other rare and metabolic indications. Silence Therapeutics plc is headquartered in London, the United Kingdom. Silence Therapeutics is traded on NASDAQ Exchange in the United States.
Silence Therapeutics Workforce Analysis
Traditionally, organizations such as Silence Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Silence Therapeutics within its industry.Silence Therapeutics Manpower Efficiency
Return on Silence Therapeutics Manpower
| Revenue Per Employee | 232.8K | |
| Revenue Per Executive | 1.7M | |
| Net Loss Per Employee | 461.6K | |
| Net Loss Per Executive | 3.4M | |
| Working Capital Per Employee | 580.3K | |
| Working Capital Per Executive | 4.2M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.